The majority of microcap funds continued their good start to 2019 and the majority of managers appear to have recovered some of the losses suffered in the final quarter of 2018. However, as a group microcap managers are trailing both comparable indexes and the performance of large-cap stocks in 2019. The... Show More
We take our monthly look at the returns of Australian Microcap Funds. The majority of funds endured double-digit and drawdowns in the Dec 18 quarter. This large drawdown in the last quarter also pulled the majority of the funds negative for the calendar year. Show More
We take our monthly look at the returns of Australian Microcap Funds. While most funds avoided the large drawdowns seen in October the majority still posted small negative absolute returns for November. We can only hope for a late Santa Clause rally to put some gloss on what looks to... Show More
Well, October 18 was a brutal month for microcaps with the S&P/ASX Emerging Companies Index closing down 10.9% for the month, Yikes! Although things have stabilised in November there has been no major recovery of the losses in October. Not that the larger cousins escaped without injury, the S&P/ASX All... Show More
Well, one of the roughest month in a long time is behind us and November has seen a bit of rebound in share markets. Microcap's were one of the worst hit in the last month, with the S&P/ASX Emerging Companies Index returning -10.91% for the month! Other indexes faired somewhat... Show More
Q1FY19 was a challenging quarter for microcap managers but the majority of managers navigated the market well with the average manager posting a return of +2.6% for the quarter. This was in contrast to S&P/ASX All Ordinaries Accumulation Index which returned +1.9% for the period. The performance of large stocks... Show More
BuildingIQ (BIQ: ASX) Is a stock that is completely off the wider investment radar for a reason that will become obvious in due course. That doesn’t mean though it’s not an interesting investment proposition. Show More
Well, the first quarter of FY19 is behind us and it has been tough for microcaps. As I alluded to in my newsletter last month, reporting season overall was pretty insipid as far as microcaps were concerned. This is reflected in the performance of the index with the S&P/ASX Emerging... Show More
MedAdvisor (MDR: ASX) operates in the healthcare IT space, specifically in improving the interaction between pharmacies, patients, drug manufacturers, doctors, and government. MDR provides a fully digital end to end experience for handling medical scripts for prescribed medication, primarily targeting chronic conditions which require ongoing medication management. Show More
Well, another reporting season has come and gone. After sifting through literally hundreds of microcap results my assessment was that it was a very average reporting season for microcaps. A few standouts with good beats to guidance and strong outlook statements but the vast majority came in soft or missed... Show More